2016
DOI: 10.1002/mds.26669
|View full text |Cite
|
Sign up to set email alerts
|

Directional deep brain stimulation of the subthalamic nucleus: A pilot study using a novel neurostimulation device

Abstract: IntroductionA novel neurostimulation system allows steering current in horizontal directions by combining segmented leads and multiple independent current control. The aim of this study was to evaluate directional DBS effects on parkinsonian motor features and adverse effects of subthalamic neurostimulation.MethodsSeven PD patients implanted with the novel directional DBS system for bilateral subthalamic DBS underwent an extended monopolar review session during the first postoperative week, in which current th… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

7
156
1
3

Year Published

2016
2016
2024
2024

Publication Types

Select...
8
1

Relationship

1
8

Authors

Journals

citations
Cited by 198 publications
(167 citation statements)
references
References 8 publications
7
156
1
3
Order By: Relevance
“…Lead displacement with lateral deviations ≥1.40 mm during subthalamic nucleus DBS were shown to be likely associated with unfavorable spread of electrical current into adjacent eloquent areas leading to extensive stimulation-induced side effects [27]. Despite good compensatory mechanisms of directional leads, Steigerwald et al [28] clearly point out that the employment of this novel technology “must never be an excuse for lowering the surgical standard and precision of surgical lead placement”. With a mean deviation of 0.76 mm, the ROSA Brain can be considered a precise tool for lead implantation that not only features high accuracy, but also high reliability.…”
Section: Discussionmentioning
confidence: 99%
“…Lead displacement with lateral deviations ≥1.40 mm during subthalamic nucleus DBS were shown to be likely associated with unfavorable spread of electrical current into adjacent eloquent areas leading to extensive stimulation-induced side effects [27]. Despite good compensatory mechanisms of directional leads, Steigerwald et al [28] clearly point out that the employment of this novel technology “must never be an excuse for lowering the surgical standard and precision of surgical lead placement”. With a mean deviation of 0.76 mm, the ROSA Brain can be considered a precise tool for lead implantation that not only features high accuracy, but also high reliability.…”
Section: Discussionmentioning
confidence: 99%
“…5 Recently, DBS electrode leads with electrode contacts that are split into 3 parts along the circumference of the electrode became available. 6,7 Distributing the stimulation among these electrode segments allows steering of the electrical field in a predefined direction. In the subthalamic nucleus, DBS by this approach theoretically allows one to steer the field away from the internal capsule while at the same time allowing a better coverage of the nucleus and relevant pathways (eg, hyperdirect pathway), with a possibly better therapeutic window.…”
Section: Eep Brain Stimulation (Dbs)mentioning
confidence: 99%
“…As such, these novel leads can widen the therapeutic window by lowering the efficacy threshold and increasing the side-effect threshold, 10,11 as indicated in a recent pilot study. 12 A larger therapeutic window allows greater programming flexibility, as the expected beneficial effects of DBS may be reached at a lower current amplitude or higher current amplitudes could be attainable before side effects appear 11 -this is important when increasing the stimulation amplitude to optimize DBS efficacy during follow-up. 13 When used chronically, directional DBS may reduce the incidence of side effects that cannot be tested intraoperatively (eg, gait, cognitive, or behavioral disturbances) 10 and in patients with a narrow therapeutic window despite good location of the lead as verified by intraoperative testing, microrecordings, or imaging, as well as in patients operated under general anesthesia precluding clinical testing (eg, for dysarthria).…”
Section: Clinical Opportunitiesmentioning
confidence: 99%